Allocating Resources for Cancer Care in Times of the Sars-CoV-2 Outbreak. Health Care Research

Medical Care of Cancer Patients During the COVID-19 Pandemic - an Analysis of Health Insurance Claims Data

The focus on treatment of COVID19 patients during the Sars-CoV-2 outbreak has most likely implications for the extent and quality of diagnosis and treatment of non-COVID19 patients. Medical care of cancer patients is a particularly sensitive area. To draw holistic conclusions, it is necessary to analyze the provision of healthcare as broadly as possible with regard to the dimensions of access, processes and outcome during the Sars-CoV-2 pandemic. This will be implemented exemplarily for the early detection, diagnosis and treatment of colorectal cancer (CRC) and pancreatic cancer (PaCa) in Saxony. Patients with diagnosis, treatment or early detection measures for type 2 diabetes (T2D), coronary heart disease (CHD) and multiple sclerosis (MS) serve as comparison groups.

Study Overview

• Status: Completed
• Conditions: Colorectal Cancer (CRC) and Pancreatic Cancer (PaCa)
• Intervention / Treatment: Other: Sars-CoV-2 outbreak

Detailed Description

For a realistic assessment, the situation will be compared with the situation before the Sars-CoV-2 pandemic while considering confounders and effect modifiers. The evaluation is based on pseudonymised routine statutory health insurance (SHI) data of the AOK PLUS for Saxony.

As data sources, SHI data of the AOK PLUS Saxony for the period 2015 to 4th quarter 2020 and publicly available data on COVID19 are used. The differentiation between incidence and prevalent diseases is based on a 4-year washout period, so that the health care situation can be compared between 2019 (pre-period) and 2020 (post-period). Patients with confirmed diagnoses of CRC and PaCa or early detection measures regarding CRC are investigated. These will be contrasted to patients with confirmed diagnoses of T2D, CHD, and MS or early detection measures regarding T2D.

The differentiation of subgroups as confounders or effect modifiers is taken into account. Subgroups are considered with respect to the factors age groups, gender, Elixhauser comorbidities, metastasis y/n, residential regions (postal code 3 digits), characteristics of the treating institution and possibly seasonal effects.

Aims:

Analysis of the differences in the health care provision situation during the Sars-CoV-2 outbreak compared to the time before.

Research questions:

1. (How) did the situation of health care for cancer patients change due to the outbreak of Sars-CoV-2? Which changes could be observed in the dimensions access to care, quality or guideline adherence in medical care and outcome?
2. Did the focus on COVID19 patients have an impact on the diagnosis or early detection of cancer in Saxony?
3. Are the observed effects differential with respect to the diseases, especially when comparing CRC and PaCa with the control group regarding T2D and CHD?

• Study Type: Observational
• Enrollment (Actual): 6500

Contacts and Locations

Study Locations

• Germany
  • Saxony
    • Dresden, Saxony, Germany, 01307
      • ZEGV

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 years and older (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Residents of Saxony, Germany with continuous health insurance coverage provided by the AOK PLUS from 2015 - 2020 with a diagnosis of colorectal cancer, pancreatic cancer, type 2 diabetes, coronary heart disease or multiple sclerosis in 2019 or 2020 according to ICD-10

Description

Inclusion Criteria:

• Resident of Saxony, Germany with health insurance coverage provided by AOK PLUS
• Diagnosis of colorectal cancer, pancreatic cancer, type 2 diabetes, coronary heart disease or multiple sclerosis between in 2019 or 2020 according to ICD-10

Exclusion Criteria:

• Change of health insurance provider between 2015 and 2020
• Born after 2014
• Deceased between 2015-2018

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of confirmed diagnoses (new cases of CRC or PaCa)	Comparison of 2019 to 2020
Number of colonoscopies	Comparison of 2019 to 2020

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of hospitalizations	Comparison of 2019 to 2020
Number of surgeries/systemic therapies related to cancer after onset of disease	Comparison of 2019 to 2020

Other Outcome Measures

Outcome Measure	Time Frame
Pathway of health care	Comparison of 2019 to 2020

Collaborators and Investigators

• Sponsor: Technische Universität Dresden
• Collaborators: German Federal Ministry of Education and Research; AOK PLUS; Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg; Ruhr-Universität Bochum
• Investigators: Principal Investigator: Jochen Schmitt, Dr. med., Technische Universitat Dresden

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 1, 2019
• Primary Completion (ACTUAL): December 31, 2020
• Study Completion (ACTUAL): December 31, 2020

Study Registration Dates

• First Submitted: July 28, 2022
• First Submitted That Met QC Criteria: July 28, 2022
• First Posted (ACTUAL): July 29, 2022

Study Record Updates

• Last Update Posted (ACTUAL): July 29, 2022
• Last Update Submitted That Met QC Criteria: July 28, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Other Study ID Numbers: CancerCOVID-HCR

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No